Oflokasin (Moxifloxacin Hydrochloride)

Moxifloxacin blocks bacterial DNA gyrase and topoisomerase IV, enzymes required for DNA replication and transcription. Inhibiting these enzymes prevents bacterial DNA from unwinding and re‑winding, leading to cell death. This mechanism provides broad‑spectrum bactericidal activity against many Gram‑positive, Gram‑negative, and atypical organisms.

The specific dose and duration of Oflokasin are determined by the treating physician based on the infection type, severity, patient weight, renal and hepatic function, and other clinical factors. Prescribers follow local guidelines and product labeling to set the appropriate regimen.

The safety of moxifloxacin in pregnancy and lactation has not been fully established. It should only be used when the potential benefit justifies any possible risk to the fetus or infant. Clinicians must evaluate each case individually and discuss alternatives when appropriate.

To request Oflokasin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Moxifloxacin offers a broader spectrum against Gram‑positive and atypical pathogens compared with older fluoroquinolones such as ciprofloxacin. It also has a higher potency, allowing once‑daily dosing in many regimens. However, safety considerations like QT prolongation and tendon risk remain similar across the class.

Oflokasin should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the solution from direct sunlight, moisture, and extreme temperature fluctuations to maintain stability.

Oflokasin is supplied as an intravenous solution and is administered by slow infusion into a vein, typically over 30–60 minutes. Administration must be performed by qualified healthcare personnel in a clinical setting, following aseptic technique and product instructions.

Serious adverse events linked to moxifloxacin include tendon rupture or tendinitis, QT interval prolongation leading to arrhythmias, severe hypersensitivity reactions such as Stevens‑Johnson syndrome, Clostridioides difficile‑associated colitis, and hepatotoxicity. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to moxifloxacin or other fluoroquinolones, those with a history of tendon disorders related to fluoroquinolone use, individuals with significant QT prolongation, and patients taking medications that strongly interact with moxifloxacin should avoid this drug unless benefits outweigh risks.